Tocilizumab after lung transplant
Treatments studied
Part of Lungs & breathing clinical trials.
This study tests whether the drug tocilizumab can help prevent your body from rejecting a new lung after transplant. It might help improve the success of your transplant by reducing immune system activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You weigh at least 30 kg (about 66 pounds).
- You are listed for or have already received a lung transplant.
- You have not had any treatment to reduce antibodies before the transplant.
- Your blood tests show a normal level of a protein called immunoglobulin G (IgG).
- You must be willing to use effective birth control if you could become pregnant.
- You have tested negative for tuberculosis (TB) or have completed treatment for it.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with serious lung disease before and after lung transplant to understand how rejection happens and what warning signs to watch for. By studying your blood, tissue samples, and imaging, researchers hope to better predict and prevent transplant rejection.
This trial tests a drug called emapalumab for people who have a sudden drop in lung function after a lung transplant. The drug targets a protein that may be causing the damage, and the goal is to treat this reaction safely.
This study tests whether adding the drug everolimus can safely reduce the amount of tacrolimus (an anti-rejection medicine) needed after a first liver transplant. This may help protect your kidneys while still preventing organ rejection.
This trial tests whether the drug tocilizumab can help treat chronic active antibody-mediated rejection after a kidney transplant. It is for people whose kidney function is still fairly good and who have certain findings on biopsy.
This early-stage study tests a long-acting form of tacrolimus (a common anti-rejection medicine) soon after lung transplant. It aims to see if it can be used safely and effectively for people receiving lung transplants at Vanderbilt (VUMC).
This trial tests a special form of tacrolimus (Envarsus) taken once daily to prevent organ rejection in people who recently received a first lung transplant. The study will follow patients for at least 12 months.
Hear when a new Lung Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.